| Febrile Neutropenia
Neupogen vs Rolvedon
Side-by-side clinical, coverage, and cost comparison for febrile neutropenia.Deep comparison between: Neupogen vs Rolvedon with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRolvedon has a higher rate of injection site reactions vs Neupogen based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rolvedon but not Neupogen, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Neupogen
Rolvedon
At A Glance
SC injection
Daily
G-CSF
SC injection
Once per chemotherapy cycle
G-CSF analog
Indications
- Febrile Neutropenia
- Leukemia, Myelocytic, Acute
- Neutropenia
- Severe congenital neutropenia
- Cyclic neutropenia
- Idiopathic neutropenia
- Hematopoietic subsyndrome of acute radiation syndrome
- Febrile Neutropenia
Dosing
Febrile Neutropenia, Leukemia, Myelocytic, Acute 5 mcg/kg/day SC injection, short IV infusion (15-30 min), or continuous IV infusion; administer at least 24 hours after cytotoxic chemotherapy.
Neutropenia (bone marrow transplantation) 10 mcg/kg/day IV infusion no longer than 24 hours; administer at least 24 hours after cytotoxic chemotherapy and bone marrow infusion.
Autologous PBPC collection 10 mcg/kg/day SC injection; administer for at least 4 days before first leukapheresis and continue until last leukapheresis.
Severe congenital neutropenia 6 mcg/kg SC injection twice daily.
Cyclic neutropenia, Idiopathic neutropenia 5 mcg/kg SC injection daily.
Hematopoietic subsyndrome of acute radiation syndrome 10 mcg/kg/day SC injection; administer as soon as possible after suspected or confirmed exposure to radiation doses >2 Gy.
Febrile Neutropenia 13.2 mg SC injection once per chemotherapy cycle, administered approximately 24 hours after cytotoxic chemotherapy; do not administer within the period from 14 days before to 24 hours after cytotoxic chemotherapy.
Contraindications
- History of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim
- History of serious allergic reactions to eflapegrastim, pegfilgrastim, or filgrastim products, including anaphylaxis
Adverse Reactions
Most common (>=5%) Pyrexia, nausea, fatigue, thrombocytopenia, bone pain, back pain, rash, dizziness, cough, dyspnea, chest pain, arthralgia
Serious Splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell disorders, glomerulonephritis, alveolar hemorrhage and hemoptysis, capillary leak syndrome, myelodysplastic syndrome, acute myeloid leukemia, thrombocytopenia, leukocytosis, cutaneous vasculitis, aortitis
Postmarketing Splenic rupture, splenomegaly, anaphylaxis, sickle cell disorders, glomerulonephritis, alveolar hemorrhage and hemoptysis, capillary leak syndrome, leukocytosis, cutaneous vasculitis, Sweet's syndrome, decreased bone density and osteoporosis, myelodysplastic syndrome, acute myeloid leukemia, aortitis, extramedullary hematopoiesis
Most common (>=20%) fatigue, nausea, diarrhea, bone pain, headache, pyrexia, anemia, rash, myalgia, arthralgia, back pain
Serious splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, capillary leak syndrome, tumor growth stimulatory effects on malignant cells, MDS and AML, aortitis
Pharmacology
Filgrastim is a recombinant human G-CSF that binds to specific cell surface receptors on hematopoietic cells, stimulating neutrophil progenitor proliferation and differentiation and enhancing end-cell functional activities including phagocytic ability, respiratory burst priming, and antibody-dependent killing.
G-CSF analog; eflapegrastim-xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration, and survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Neupogen
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
Rolvedon
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Neupogen
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Rolvedon
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Neupogen
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (1/3)
Rolvedon
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availablePAN: Neutropenia (Medicare)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NeupogenView full Neupogen profile
RolvedonView full Rolvedon profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.